FLAMINGO THERAPEUTICS
Last board
7 directors, 1 in day-to-day management, 1 auditor, last change in 2023Chair of the board and director
chair of the board appointed by deed of 28-04-2023
director in office according to the deed of 20-04-2023
Biotech Fonds Vlaanderen
Director, permanent representative Tine Bekaert
appointed by deed of 20-04-2023
BPIFRANCE INVESTISSEMENT SAS
Director, permanent representative Benoît Barteau
appointed by deed of 20-04-2023
Director and CEO, permanent representative Stéphane van Rooijen
director appointed by deed of 20-04-2023
CEO appointed by deed of 28-04-2023
KPMG Bedrijfsrevisoren BV/SRL / KPMG Réviseurs d'Entreprises BV/SRL
Statutory auditor, permanent representative Olivier Declercq
appointed by deed of 22-01-2024
- Day-to-day management
- Toulon BV
- Signing authorityThe articles say who may bind the company, for example by signing a contract.
- Two directors jointlydeed of 20-04-2023
Permanent representatives 3
Benoît Barteau
Permanent representative, for BPIFRANCE INVESTISSEMENT SAS
appointed by deed of 20-04-2023
Mandates through the years
17 names, the dashed line is todayRémi Droller
Director
Director
Christopher Mirabelli
Director, Chair of the board
Director, Chair of the board
Biotech Fonds Vlaanderen
Director
Director
BPIFRANCE INVESTISSEMENT SAS
Director
Director
Georges Gemayel
Director
Director
Henry Bradford Skinner
Director
Director
Toulon BV
Director, CEO
Director, CEO
KPMG Bedrijfsrevisoren BV/SRL / KPMG Réviseurs d'Entreprises BV/SRL
Statutory auditor
Statutory auditor
Bennett Clarence
Director
Director
Brett Paul Monia
Director
Director
Garrett Michael
Director
Director
Jean Marie Franchi
Director
Director
ParticipateMaatschappij Vlaanderen NV
Director
Director
Vanpoucke Griet
Director
Director
BDO Audit Sud & Est
Onafhankelijke commissaris in het kader van de fusie
Onafhankelijke commissaris in het kader van de fusie
BDO Bedrijfsrevisoren BV - Réviseurs d'Entreprises SRL
Onafhankelijke commissaris in het kader van de fusie
Onafhankelijke commissaris in het kader van de fusie
Roderick Verhelst
Director
Director
LeadershipBoardStatutory auditorEarliermandate already running before its first mentionend not dated
Mandates as a list
- Rémi Droller
- Director, from 04-07-2019 to date
- Christopher Mirabelli
- Director, from 22-12-2020 to date
- Chair of the board, appointed by deed of 28-04-2023, still in office
- Biotech Fonds Vlaanderen
- Director, since before 31-12-2022
- BPIFRANCE INVESTISSEMENT SAS
- Director, since before 31-12-2022
- Georges Gemayel
- Director, since before 31-12-2022
- Henry Bradford Skinner
- Director, since before 31-12-2022
- Toulon BV
- Director, since before 31-12-2022
- CEO, appointed by deed of 28-04-2023, still in office
- KPMG Bedrijfsrevisoren BV/SRL / KPMG Réviseurs d'Entreprises BV/SRL
- Statutory auditor, from 27-10-2023 to date
- Bennett Clarence
- Director, from 22-12-2020 to 20-04-2023
- Brett Paul Monia
- Director, from before 31-12-2022, no longer listed in the 2025 annual accounts
- Garrett Michael
- Director, from 04-07-2019 to 20-04-2023
- Jean Marie Franchi
- Director, from before 31-12-2022, no longer listed in the 2025 annual accounts
- ParticipateMaatschappij Vlaanderen NV
- Director, appointed by deed of 27-01-2022, until 20-04-2023
- Vanpoucke Griet
- Director, from 27-01-2020 to 20-04-2023
- BDO Audit Sud & Est
- Onafhankelijke commissaris in het kader van de fusie, appointed by deed of 27-12-2022, no longer listed in the 2025 annual accounts
- BDO Bedrijfsrevisoren BV - Réviseurs d'Entreprises SRL
- Onafhankelijke commissaris in het kader van de fusie, from 27-01-2020, no longer listed in the 2025 annual accounts
- Roderick Verhelst
- Director, from 27-01-2020 to 03-12-2021
Control
Shareholder in 2024
6.95%
This company
FLAMINGO THERAPEUTICS
Equity €15.8m
Loss €13.4m in 2025
Capital
- Capital
- €59,331,771.87
- Shares
- 12,112,495
- Contribution per share
- €4.90
- Equity per share
- €1.30 in 2025
- Source
- 2025 annual accounts
Owners through the years
as the annual accounts name themOwners as a list
- BIOTECH FONDS VLAANDEREN
- Participatiemaatschappij Vlaanderen
- VLAAMS INSTITUUT VOOR BIOTECHNOLOGIE - FLANDERS INSTITUTE FOR BIOTECHNOLOGY
Source: lists of holdings in the owners' accounts
Articles of association
- DurationMost companies exist for an unlimited period, until they are dissolved.
- Unlimiteddeed of 28-04-2023 (in Dutch)
- Board ruleThese rules set how the board is made up, meets and takes decisions.
- At most 10 directors“Alleen of gezamenlijk zoals raad bepaalt”deed of 28-04-2023 (in Dutch)
- Transfer restrictionThis rule says whether shareholders may sell their shares freely or need approval first.
- “Zelfde overdrachtsbeperkingen en -verplichtingen als overeenkomstige Preferente Aandelen, enkel samen met alle onderliggende overeenkomstige…”deed of 20-04-2023 (in Dutch)
- Annual meetingThe shareholders approve the annual accounts, among other things, at the annual meeting.
- “Artikel 22: Organisatie en bijeenroeping De gewone algemene vergadering wordt jaarlijks gehouden op de eerste dag van de maand van juni, om…”deed of 28-04-2023 (in Dutch)
- Liquidation ruleIn a liquidation the creditors are paid first. What is left goes to the shareholders.
- “Alle verrichtingen vermeld in de wet, tenzij algemene vergadering anders besluit bij gewone meerderheid van stemmen”deed of 28-04-2023 (in Dutch)
- Custody of recordsThe books and records are kept for at least five years after liquidation. The articles set where.
- “9 Wembley Court, Mount Laurel, New Jersey, Verenigde Staten van America”deed of 31-03-2026 (in Dutch)
Capital transactions
Capital over time
- 03-07-2024 Capital increase of €6,000,000
- 03-07-2024 Capital increase of €4,000,000
- 03-07-2024 Capital increase of €1,846.60 · “uitoefening van inschrijvingsrechten”
- 03-07-2024 Capital increase of €1,316.29 · to €59,331,771.87 · “uitoefening van inschrijvingsrechten”
- 21-08-2023 Capital increase of €1,846.60 · to €58,413,346.60 · “overschrijving op een bijzondere rekening”
- 28-04-2023 Capital increase of €4,000,000 · 500,000 new shares at €8 per share · in cash
- 20-04-2023 Capital increase of €6,000,000 · to €54,411,500 · 750,000 new shares · in cash
- 28-09-2021 Capital stated in the deed · 563,190 shares